Brief: Ipsen Confirms 2026 Guidance
23/04/2026 06:05
April 23 (Reuters) - Ipsen SA IPN.PA: CONFIRMS FULL-YEAR 2026 GUIDANCE Q1 2026 TOTAL SALES UP 22.6% AT CONSTANT EXCHANGE RATES, 17.0% AS REPORTED Q1 REVENUE EUR 1,074.9 MILLION Source text: ID:nGNEc5bCQM Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio